Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid – with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan
Aditxt, Inc. (NASDAQ: ADTX) has signed an asset purchase agreement with Cellvera, granting Aditxt a 50% stake in Global Response Aid (GRA), a partnership with Agility. The deal involves a total transaction value of $24.5 million, which includes the forgiveness of a $14.5 million loan and $10 million in cash, alongside future royalties over seven years. This strategic acquisition aims to expand Aditxt’s capabilities in developing effective antiviral therapies, particularly focusing on the drug Avigan, which is licensed for use in multiple markets excluding Japan, China, and Russia. The agreement is contingent upon various approvals, including board and regulatory consents. Aditxt's CEO emphasizes that this acquisition is pivotal for driving future growth and addressing the rising demand for antiviral solutions.
- Acquisition expands Aditxt's portfolio to include antiviral therapies.
- Strategic partnership with Agility enhances logistical capabilities.
- Potential revenue growth through royalties over the next seven years.
- Exclusive license for Avigan supports market entry into antiviral treatments.
- The transaction's closing is subject to multiple conditions, creating uncertainty.
- Future financing needs may strain Aditxt's financial resources.
-
This agreement is a significant step for
Aditxt as it expands its portfolio to include innovative therapies for infectious diseases; -
Aditxt will partner with global logistics leader Agility to address a growing global market need for effective antivirals
The closing of the transaction remains subject to a number of conditions, including but not limited to, among others, approval by Aditxt’s board of directors to enter into this transaction, financing of the purchase price, regulatory approvals for the transfer of shares, the resolution and satisfaction of all of Cellvera’s creditors inclusive of those creditors who have initiated claims, and securing the rights to additional 3rd-party IP assets. No assurance can be given that all of the conditions to closing will be obtained or satisfied, or that the transaction will ultimately close.
“We believe this acquisition has the potential to help drive Aditxt’s strategic revenue and growth, as we move forward to help address a growing market need for more effective antivirals,” said
GRA CEO
About
Aditxt,® Inc. (NASDAQ: ADTX) is a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system. Aditxt’s mission of “Making Promising Innovations Possible, Together” is defined by our growing ecosystem of research institutions, global industry partners and shareholders who inform and inspire our mission. Aditxt’s diverse innovation portfolio includes: Adimune, Inc.™, developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc.™, focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta, Inc.™, which offers personalized immune monitoring intended to be informative for a wide range of health conditions, including hereditary cancer, wounds and cardiomyopathy.
For more information, visit the Company’s websites at www.Aditxt.com, www.Adimune.com and www.Pearsanta.com. Follow us on LinkedIn for the latest company news.
About Agility
Agility is a global leader in supply chain services, infrastructure, and innovation with 45,000+ employees across six continents. The company is a pioneer in emerging markets and specializes in growing and scaling businesses. Agility’s companies include the world’s largest aviation services company (
For more information visit: www.agility.com. Twitter: twitter.com/agility. LinkedIn: linkedin.com/company/agility. YouTube: youtube.com/user/agilitycorp
About Global Response Aid (GRA)
Global Response Aid, based in
For more information visit: www.globalresponseaid.com
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product and business development; the Company’s ability to finance and execute on its strategic M&A initiatives; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20230420005436/en/
Media and Investor Relations Contact:
IR@Aditxt.com
Source:
FAQ
What is the significance of Aditxt's recent acquisition of Global Response Aid?
What are the financial terms of Aditxt's deal with Cellvera?
What is Avigan and its role in Aditxt's strategy?
How does Aditxt plan to finance the acquisition of Global Response Aid?